Echo Therapeutics has announced the positive results from a clinical study of its Symphony transdermal continuous glucose monitoring system in patients with type 1 and type 2 diabetes.

The feasibility study, involving 20 adult diabetecs, was designed to assess the performance of the Symphony system in an outpatient setting at a clinical research organisation.

The study confirmed that Symphony successfully monitors the broad range of blood glucose values seen in people with diabetes.

The company also plans to conduct a study in critical care patients.